Trials / Completed
CompletedNCT03362242
Study of ARO-AAT in Normal Adult Volunteers
A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin Levels in Normal Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Arrowhead Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-AAT in healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARO-AAT Injection | Single or multiple doses of ARO-AAT by subcutaneous (sc) injections |
| OTHER | Sterile Normal Saline (0.9% NaCl) | Calculated volume to match active comparator |
Timeline
- Start date
- 2018-03-12
- Primary completion
- 2018-10-23
- Completion
- 2020-03-21
- First posted
- 2017-12-05
- Last updated
- 2025-12-24
Locations
1 site across 1 country: New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03362242. Inclusion in this directory is not an endorsement.